Pfiz­er/Mer­ck KGaA launch sol­id tu­mor com­bo study with Leap; As­traZeneca and Im­munomedics to test ADC can­cer com­bo

→ Pfiz­er and Mer­ck KGaA are team­ing up with Leap Ther­a­peu­tics $LP­TX to eval­u­ate the small Cam­bridge, MA-based com­pa­ny’s drug in a com­bo with Baven­cio (avelum­ab) and chemo. Leap is de­vel­op­ing a drug called TRX518, a hu­man­ized mon­o­clon­al an­ti­body that binds to the glu­co­cor­ti­coid-in­ducible TNF-su­per­fam­i­ly re­cep­tor. It’s be­lieved to boost the body’s an­ti-tu­mor re­sponse, and will be test­ed in this com­bo in pa­tients with sol­id tu­mors. Un­der the terms of the deal, Leap will con­duct a Phase I/II study, with en­roll­ment start­ing in Q1 2019.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.